Topical and Oral Voriconazole in the Treatment of Fungal Keratitis by Lee, Sang Joon et al.
46
접수번호: 07-075 Korean Journal of Ophthalmology 2009;23:46-48
ISSN : 1011-8942 
DOI : 10.3341/kjo.2009.23.1.46
Topical and Oral Voriconazole
in the Treatment of Fungal Keratitis
Sang Joon Lee, MD, Jung Joo Lee, MD, Shin Dong Kim, MD
Department of Ophthalmology, College of Medicine, Kosin University, Busan, Korea
We describe two patients with fungal keratitis refractory to standard antifungal therapy whose conditions were 
managed with voriconazole.
The first case is a patient with endophthalmitis and corneal ulcer due to Candida parapsilosis after receiving a 
corneal transplant. The patient was treated with amphotericin but showed no signs of improvement. Topical 
voriconazole, oral voriconazole, and intravitreal voriconazole yielded signs of improvement. The second case is a 
63-year-old male who underwent a month of empiric treatment with 0.2% topical amphotericin for fungal keratitis 
but showed no signs of improvement. Treatment was then provided with 1% voriconazole. Both cases showed 
effective treatment with voriconazole.
Voriconazole may be considered as a new method to treat fungal keratitis refractory to standard antifungal 
therapy.
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Voriconazole has been reported to be effective in the treat-
ment of fungal keratitis.
1-4 Jang et al.
5 reported effective 
treatment of candida chorioretinitis with voriconazole. Sponsel 
et al.
6 reported topical voriconazole as a novel treatment for 
fungal keratitis. Voriconazole has the broad spectrum coverage 
of the azole antifungals and has good intraocular penetration 
following oral administration. We report the use of topical, 
oral, and intravitreal voriconazole in two patients with fungal 
keratitis and fungal endophthalmitis.
Case 1
A 60-year-old man was admitted because of visual distur-
bances and ocular pain following penetrating keratoplasty in 
the right eye for a corneal chemical burn.
On slit lamp examination, we observed a feather-like 
corneal opacity, corneal infiltrations, and epithelial defects. 
Fungal keratitis was suspected and corneal scrapings were 
taken that grew C. parapsiolosis. Subconjuctival amphoteri-
cin B (1 mg), topical amphotericin B 0.125%, and levofloxaxin 
0.5% were subsequently administered every hour for 16 weeks. 
We discontinued use of the eye solutions upon observing 
signs of clinical improvement and stabilization. However, 5 
days later the lesion recurred. The patient was restarted on 
and maintained on a topical amphotericin B treatment (0.125% 
twice daily) for 1 year. In addition, levofloxaxin 0.5% (three 
times daily) and fluorometholone 0.1% (twice daily) were 
administered for 1 year. The lesion did not progress, but there 
was no change in corneal infiltration. On examination one 
year later, an elevated corneal lesion and increased corneal 
infiltration with a yellow color were observed despite the 
topical amphotericin B treatment. Seven days later anterior 
chamber hypopyon and vitreous opacity on a B-scan were 
observed (Fig. 1A). We immediately performed an intravitreal 
injection of amphotericin B 5 µg/0.1mL and vancomycin 1 
mg/0.1mL. The next day there were still no signs of clinical 
improvement. Intravitreal voriconazole 80 µg/0.1mL and 
ceftazidime 2 mg/0.1mL were injected and topical voriconazole 
1% was administered every 2 hours. Oral voriconazole 200 mg 
(twice daily) was also administered for 7 days. The patient 
discontinued the oral voriconazole because of abdominal 
pain, dry mouth, and scaling of the oral mucosa. The topical 
voriconazole was tolerated despite complaints of ocular 
burning. The patient was treated topically for 6 weeks, after 
which the corneal lesion and endophthalmitis had improved. 
The corneal opacity and endophthalmitis remained as compli-
cations of the lesion (Fig. 1B). The patient subsequently 
underwent another penetrating keratoplasty and demonstrated 
a visual acuity of 0.1 at 10 months follow-up with no signs of 
recurrence.
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Fig. 1. (A) Approximately 1 year later, anterior chamber hypopyon and vitreous opacity on B-scan were observed. (B) After the patient was 
treated with 1% topical voriconazole for 6 weeks the corneal lesion and endophthalmitis improved. The corneal opacity persisted as a compli-
cation of the lesion and endophthalmitis. (C) The patient underwent another penetrating keratoplasty and showed a visual acuity of 0.1 at fol-
low-up. There was no sign of recurrence.
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Fig. 2. (A) On initial examination, a feathered corneal infiltration and a corneal ulcer were observed. (B) After 10 days the corneal epithelial 
appeared healed; however, there was no change in the corneal infiltration. (C) After 13 weeks we observed complete healing of the corneal epi-
thelium and resolution of the corneal infiltrate; however, the corneal opacity persisted.
A 60-year-old man was referred to us because of a lack of 
improvement after a month of empiric treatment with topical 
amphotericin B for fungal keratitis. On our initial examination 
we observed a feathered corneal infiltration and a corneal 
ulcer (Fig. 2A). Corneal scrapings were taken. We started 
treatment with topical amphotericin B 0.125% and moxifloxacin 
0.5%. After 10 days the culture revealed no growth and the 
corneal epithelium appeared healed; however, there was no 
change in corneal infiltration (Fig. 2B). Because of a lack of 
improvement in the corneal lesion a month later, a new treat-
ment regimen was initiated with topical voriconazole 1% 
administered every hour. The patient complained of ocular 
burning but tolerated the treatment. Clinical improvement 
was observed two weeks later with healing of the corneal 
epithelium. Six weeks later we observed a decreasing density 
of the infiltrate and healing of the corneal epithelium; the 
topical voriconazole was decreased to twice daily. The patient 
was treated topically for 13 weeks. Following completion of 
the therapy, complete healing of the corneal epithelium and 
resolution of the corneal infiltrate were observed; however, 
the corneal opacity persisted (Fig. 2C).
Discussion
Voriconazole, a derivative of fluconazole, is a new triazole 
antifungal agent.
4 Like other triazoles, this voriconazole inhibits 
cytochrome P450 demethylase, which is essential for the 
synthesis of ergosterol. It is hypothesized that this adversely 
affects the permeability of the fungal cell membrane.
7 Vorico-
nazole has excellent oral bioavailability and a broad spectrum 
of activity. Therapeutic aqueous and vitreous levels are 
achieved after oral administration of voriconazole.
8 Voriconazole 
showed lower MICs compared to other antifungal agents 
when tested against five corneal isolates of Scedosporium 
apiospermum,
2 and it had the best in vitro susceptibility profile 
for 34 common fungal pathogens compared to other antifungal 
agents.
9 Gao et al.
10 reported that direct intravitreal voriconazole 
injections of 25 µg/mL (equivalent to 100 mg per injection in 
a human eye) caused no electroretinographic or histopathologic 
abnormalities in rodent retinas. Kramer et al.
11 reported that 
intravitreal injection of voriconazole (100 µg/0.1mL) with 
pars plana vitrectomy was an effective therapy for aspergillus 
endophthalmitis. Lee et al.
7 reported a case of drug-resistant 
penicillium endophthalmitis that was treated with intravitreal 
voriconazole injection (50 µg/ 0.1mL). In these cases, intravitreal 
voriconazole (80 µg/0.1mL) achieved effective concentrations. 
Voriconazole has been shown to be highly effective against 
filamentous organisms and is more potent in invasive asper-
gillosis than amphotericin B.
12,13 According to a report by Jang 
et al.,
5 voriconazole is also effective against candida chorio-Korean J Ophthalmol Vol.23, No.1, 2009
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retinitis. Ozbek et al.
14 reported one case of Alternaria keratitis 
that showed improvement with 1% topical voriconazole. In 
contrast, Giaconi et al.
15 reported two cases of fungal keratitis 
caused by Fusarium oxysporum and Colletotrichum dematium 
that did not respond to treatment with 1% topical voriconazole. 
Our report indicates that 1% voriconazole is an effective 
treatment for candida spp. and unknown fungal keratitis. In 
conclusion, voriconazole is a new, promising therapy for fungal 
keratitis refractory to standard antifungal agents. Nevertheless, 
more clinical trials will be necessary to investigate the 
effectiveness of systemic voriconazole and corneal trans-
plantation.
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